Lung cancer’s endogenous tumour defence largely happens due to different reasons such as the altering residues at drug binding sites, ALK and ROS1 rearrangements, and mutations in N-RAS, K-RAS, B-RAF, EGFR and RET [112]. The gene discussed is KRAS; the disease is lung carcinoma.